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• To reduce the time  needed for  Niemann-Pick Type C (NPC) diagnosis
• To identify the classic NPC symptoms in children
• To encourage the multispecialty collaboration when NPC is suspected
• To describe the current management and treatment options for NPC
Objectives
Introduction to Niemann-Pick Disease
• Inherited condition involving abnormal lipid metabolism
• Harmful amounts of lipids accumulate in the 
spleen, liver, lungs, bone marrow, and brain
• Autosomal recessive pattern of inheritance 
(two copies of the gene must be present)
• Four variants: A, B, C1, and C2
Niemann-Pick Disease
Vanier MT. Niemann-Pick Diseases. In: Dulac O, Lassonde M, Sarnat HB, eds. Handbook of Clinical Neurology. 3rd ed. Elsevier B.V; 2013:1717-21. 
Niemann-Pick Disease
Vanier MT. Niemann-Pick Diseases. In: Dulac O, Lassonde M, Sarnat HB, eds. Handbook of Clinical Neurology. 3rd ed. Elsevier B.V; 2013:1717-21. 
• NPC1 gene encodes a protein that plays a critical role in 
regulation of intracellular cholesterol trafficking
• NPC2 gene encodes a protein that binds and transports 
cholesterol (this is not fully understood)
• SMPD gene carries instructions for cells to produce 
sphingomyelinase, which processes lipids
• Mutations lead to deficiency of sphingomyelinase and 
accumulation of cholesterol and lipids
Two distinct entities
Types A and B: mutated SMPD1 gene
Types C1 and C2: mutated NPC1 or NPC2 gene
Niemann-Pick Disease Type C
• NPC occurs with a minimal incidence of 1:120,000 live births1
– This number is based on 63 cases diagnosed in French hospitals between 2000-
2009 versus the number of total births during this period
– The prevalence is higher (1:104,000) when including prenatal cases from terminated 
pregnancies
• This is considered an under-estimate of the true prevalence of NPC, as 
atypical phenotypes may be not be clinically suspected1
• There are reports that the prevalence of NPC is approximately 500 
patients worldwide and 200 patients in the United States2,3
Niemann-Pick Type C (NPC) is a Fatal, 
Progressive, Neurodegenerative Disorder
1. Vanier MC, et al. Orphanet J Rare Dis. 2010;5(16):1-18. 2. National Niemann-Pick Disease Foundation Inc. http://nnpdf.org/overview/#NPC Accessed June 29, 2017. 3. Miglustat therapy for 
Nieman-Pick Type C disease. UCM248677. 
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM248677.pdf. Accessed June 29, 2017.
• The Niemann-Pick type C1 (NPC1) gene is responsible for most (~95%) cases of NPC 
disease1
– NPC1 is located on chromosome 18 at cytogenetic band 18q11-122,3
– NPC2 is mapped at chromosome 14q24.3
• The NPC1 gene encodes a small soluble lysosomal protein involved in cholesterol 
binding3
In Most Cases, NPC is Caused by Mutations in Two Genes:
NPC1 (95% of Cases) or NPC2 (5% of Cases)
1. Vanier MT, et al. Am J Hum Genet. 1996;58:118-25. 2. Carstea ED, et al. Science. 1997;277:228-31. 3. Ioannou YA. Mol Genet Metab 2000;71(1-2):175-81. 
• Both NPC1 and NPC2 have identical biochemical patterns, suggesting that the two 
proteins function together in cellular transport of cholesterol, glycolipids, etc1
– Their precise functions and relationship remain unclear and are currently the subject of intense 
investigation
• NPC mutations result in intracellular lipid accumulation in various tissues, including the 
brain, liver, and spleen1,2
In Most Cases, NPC is Caused by Mutations in Two Genes: 
NPC1 (95% of Cases) or NPC2 (5% of Cases), cont.
1. Maue RA, et al. Hum Mol Genet. 2012;21(4):730-50. 2. Praggastis M, et al. J Neurosci. 2015;35(21):8091-106. 
Topological model of the NPC1 protein 
and locations of NPC1 mutations
Figure reproduced from Vanier MT, Millat G. Clin Genet 2003;64(4):269-81.
Topological model of the NPC1 protein and locations 
of NPC1 mutations
Figure reproduced from Vanier MT, Millat G. Clin Genet 2003;64(4):269-81.
Pathophysiology
• NPC1 is a transmembrane protein located on the LE/L 
compartments where it regulates cholesterol efflux
• The cholesterol trafficking defect occurs when 
endocytosed LDL-cholesterol becomes sequestered in 
lysosomes around the cell nucleus
• Transport from these perinuclear lysosomes is delayed, 
resulting in excess accumulation of unesterified 
cholesterol
• This accumulation may result in a deficiency in cell 
membrane cholesterol with subsequent membrane 
dysfunction/a triggering of apoptosis
In NPC Disease, the Central Biochemical Defect is Impaired Intracellular 
Lipid Trafficking 
LDL, low-density lipoprotein; LDLR, low-density lipoprotein receptor; LE, late endosomes; L, lysosomes. 
Maetzel D, et al. Stem Cell Reports. 2014:2(6):866-880. 2. Liu B. Clin Lipidol. 2012;7:289-301. 
Cholesterol uptake and processing in the cell
Figure reproduced from Liu B, et al. J Lipid Res. 2007;48(8):1710-23.
holesterol uptake and processing in the cell
Figure r produced from Liu B, et al. J Lipid Res. 2007;48(8):1710-23.
• Loss-of-function mutation in either NPC1 or NPC2 results in disruption of cholesterol 
transport out of the LE/L, causing accumulation of cholesterol
• Cholesterol accumulation was ~7-fold greater in NPC1-/- mice compared with control 
animals, due to daily sequestration of 67 mg cholesterol per kg in various organs2
• LDL uptake from the circulation was not altered in NPC1-/- mice, and cholesterol 
absorption was not increased2
• Furthermore, administration of a sterol-binding agent to NPC1-/- mice increased 
cholesterol movement out of the LE/L in the liver from near 0 to 233 mg/day/kg3
• This suggests that NPC1 deletion causes accumulation of cholesterol by disrupting 
cholesterol transport out of the LE/L
The NPC1 Deletion (NPC1-/-) Mouse Model Demonstrates Accumulation 
of Cholesterol Within Tissues1,2
LE, late endosomes; L, lysosomes
1. Liu B, et al. J Lipid Res. 2007;48(8):1710-23. 2. Xie C, et al. Proc Natl Acad Sci USA. 1999;96(21):11992-7. 3. Liu B, et al. Proc Natl Acad Sci USA. 2009;106(7):2377-82. 
Animal and Organ Weights, Cholesterol Pool Sizes, and Rates of Dietary 
Cholesterol Absorption in NPC1-/- Mice
aSignificant difference between NPC-/- / LDLR+/+ and control (NPC+/+ / LDLR+/+) mice.





Weight of whole animal, g 21.3 ± 0.3 17.4 ± 0.3a
Weight of liver, g 1.20 ± 0.03 1.33 ±0.037a
Weight of brain, g 0.44 ±0.01 0.38 ± 0.03a
Cholesterol pool at day 1, mg/kg 1725 ± 22 2453 ± 35a
Cholesterol pool at 7 weeks, mg/kg 2165 ± 47 5669 ± 173a
Cholesterol sequestration, mg/day per kg 9.2 67.0
Cholesterol absorption, mg/day per kg 14 ± 2 8 ± 2a
• A mouse model (NPC1nmf164) of a point mutation in NPC1
has been described, which causes a single amino acid 
change in a region of the NPC1 protein where ~1/3 of 
mutations in patients with NPC are found. NPC1nmf164 mutant 
mice demonstrate cholesterol accumulation in the liver, 
spleen and brain
• Cholesterol accumulation was also evident in a mouse model 
of the most common NPC1 mutation found in patients with 
NPC (p.I1061T)
– A broad range of lipids including unesterified cholesterol 
accumulated in the liver
– Cholesterol storage was observed throughout all layers of the 
neocortex 
Mutations in the NPC Gene Lead to Accumulation of Cholesterol and 
Other Lipids in Various Tissues Such as the Brain, Liver, and Spleen
Maue RA, et al. Hum Mol Genet. 2012;21(4):730-50. 
Figure reproduced from Reid PC et al. J Lipid Res. 2004;45(3):582-91.
Clinical Presentation
Average Age at Diagnosis is 10 Years; Average Age at Death is 16 Years
NPC Disease US Database: 
Delayed Diagnosis
Average age at diagnosis is 10.4 years
It can take up to 10 
years for a 
diagnosis
Death occurs 
between 8 and 25 





of patients are 
diagnosed before 
age 6.9 years
of patients die 
before age 12.5 
years
NPC Disease US Database: 
Poor prognosis
Garver WS, et al. Am J Med Genet. 2007; Part A 143A:1204-1211.
Average age at death is 16.2 years
• In NPC, cholesterol accumulation in the CNS results in progressive and irreversible neuronal 
degradation and neurological manifestations
• Early onset of neurological symptoms is directly linked to severity of NPC
NPC is Often Categorized by the Age of Onset of the First Neurological 
Symptoms (Early Infantile, Late Infantile, Juvenile, and Adult)
CNS, central nervous system. Figure reproduced from Vanier MT. Orphanet J Rare Dis 2010;5:16. 
Schematic of the main forms of NPC, with emphasis on type and age of onset of first neurological symptoms
• NPC has a variable presentation, including visceral, neurological, and psychiatric signs and symptoms 
and can present at any age1,2
– Younger patients tend to present predominantly with visceral manifestations
– Neurological and psychiatric symptoms become more common with increasing age





-Prolonged neonatal cholestatic 
jaundice
-Hydrops fetalis or fetal ascites
-Pneumopathologies (aspiration 
pneumonia, alveolar lipidosis, 
interstitial lung involvement)
-Mild thrombocytopenia



















1. Vanier MC. Orphanet J Rare Dis. 2010;5(16):1-18. 2. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12.
• Progressive neurodegeneration results in disabling neurological and psychological 
symptoms like ataxia, dystonia, hypotonia,vertical supranuclear gaze palsy, gelastic 
cataplexy, dysarthria, dysphagia, cognitive decline, pre-senile cognitive 
decline/dementia and psychosis1
• Mortality usually results from the neurological manifestations of the disease, most 
commonly dysphagia (and consequent aspiration pneumonia), and is exacerbated by 
the delays in diagnosis2
Neurological Manifestations Can Lead to Mortality
1. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12. 2. Walterfang M, et al. Orphanet J Rare Dis. 2012;7:76. 
• Dysphagia is a common neurological symptom in NPC patients (prevalence ~55%)1
• The risk of aspiration pneumonia is significantly increased in patients with dysphagia,2
and the most common reported cause of death in patients with NPC is 
bronchopneumonia2,3
• The average delay in diagnosis from onset of neurological manifestations is 4.1 years4
Diagnostic Delay Exacerbates Morbidity and Mortality
1. Walterfang M, et al. Orphanet J Rare Dis. 2012;7:76. 2. Jan MM, et al. J Child Neurol. 1998;13:75-8. 3. Kelly DA, et al. J Pediatr. 1993;123:242-7. 4. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12. 
Age at neurological 
onset, years
n Mean (SD)




Patients with neurological 
manifestations
145 10.9 (9.8) 140 15.0 (12.2) 4.1
Early infantile (<2 years) 16 0.8 (0.6) 16 1.0 (1.0) 0.2
Late infantile (2 to <6 years) 45 4.2 (1.3) 43 8.2 (7.4) 4.0
Juvenile (6 to <15 years 45 9.7 (2.8) 41 13.8 (5.0) 4.1
Adolescent/adult (≥15 years) 39 24.0 (8.9) 39 29.7 (10.0) 5.7
Age at Neurological Onset and Age at Diagnosis for Patients With 
Neurological Manifestations From NPC
SD, standard deviation.
Table reproduced from Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12.
• Neurological involvement defines the disease severity in most patients but is typically 
preceded by systemic signs (cholestatic jaundice in the neonatal period or isolated 
spleno- or hepatosplenomegaly in infancy or childhood)1,2
Progressive Hepatosplenomegaly is Present in ~50% of Patients, With 
Variable Intensity


















Overall hepatomegaly during 
infancy (50/127; 39%); 
splenomegaly (69/127; 54%)
1. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12. 2. Varnier MT. Orphanet J Rare Dis. 2010;5:16.
Clinical Diagnosis
• Low disease awareness and heterogeneous clinical presentation impedes diagnosis, 
often resulting in misdiagnosis and/or delay in therapy initiation
Highly Variable Clinical Presentation Leads to a Lack of 
Detection and Diagnosis
Figure reproduced from Klunemann H, et al. Eur Neuro Rev. 2011;12-15.
Klunemann H, et al. Eur Neuro Rev. 2011;12-15.
Symptom progression from onset of disease and common misdiagnoses of NPC
• Time to diagnosis is limited by the symptomology exhibited by patients and speed of recognition by 
healthcare professionals
• Greater awareness of the disease and its manifestations among healthcare professionals may 
expedite referral to specialist centers
Diagnosis of NPC is Often Delayed, and NPC is Often Confused 
With Other Diseases
Klunemann H, et al. Eur Neuro Rev. 2011;12-15.
Average time to diagnosis from symptom onset:
9 months 6 years Up to 19 years






• Declining academic performance
• Hallucinations
• Aggressive behaviour
• Paranoia (often in 
teens)
Average Delay in NPC Diagnosis of 4-6 Years 
• Laboratory tests include biochemical testing of intracellular cholesterol homeostasis, DNA tests for NPC gene 
mutations, and skin biopsy
Diagnosis of NPC is Often by Clinical Exclusion and Confirmatory 
Biomarker Testing in Addition to Important Genetic Evaluation
• A key diagnostic test is demonstration of impaired 
intracellular cholesterol transport by filipin staining of 
fibroblasts cultured from patient skin biopsies1,2
• NPC+ cells show up as strongly fluorescent cholesterol-
filled perinuclear vesicles under fluorescence microscopic 
examination1,2
• This is the classical cholesterol storage pattern, 
demonstrated in >80% of cases3
• Other patients show a variant biochemical phenotype with 
less pronounced and more variable cholesterol storage1-3
• DNA tests for NPC1/NPC2 mutation should be performed in 
parallel with filipin staining1
• Although significant advances have been made in genetic 
sequencing of NPC1/NPC2, filipin staining remains the 
primary diagnostic test
Visualization of unesterified cholesterol by filipin staining of 
fibroblasts from a typical patient with NPC1 mutations (A) and 
a typical patient with NPC2 mutations (B)
Figure reproduced from Vanier MT, Latour P. Method Cell Biol 2015;126:357-75
1. Patterson MC, et al. Mol Genet Metab. 2012;106:330-44. 2. Vanier MT, et al. Biochim Biophys Acta. 1991;328-37. 3. Patterson MC, et al. Orphanet J Rare Dis. 2013;8:12. 
• Biomarkers could potentially substantially 
reduce diagnostic delays and may also 
prove useful in establishing disease 
severity and monitoring disease 
progression and response to therapeutic 
interventions1
• Recently, biomarkers have been 
developed to diagnose NPC that are less 
invasive, cost-effective, and easier to 
perform than conventional NPC 
diagnostic methods1






1. Papandreou A, et al. Ther Adv Neurol Disord. 2016;9(3):216-29. 2. Kannenberg F, et al. J Steroid Biochem Mol Biol. 2017;169:54-60. 3. Porter FD, et al. Sci Transl Med. 2010;2(56):56ra81. 
4. Welford RWD, et al. PLoS One. 2014;9(12):e114669. 5. Mazzacuva F, et al. FEBS. 2016;590(11):1651-62. 6. Liu N, et al. Toxicol Appl Pharmacol. 2014;279(3):467-76. 
Diagnosis of NPC is Often by Clinical Exclusion and Confirmatory 
Biomarker Testing in Addition to Important Genetic Evaluation, cont.
• Experts recommend initiating specific therapy at the first 
appearance of neurological symptoms
• Given the heterogeneous presentation of NPC, 
international experts developed a simple and reliable 
screening tool which aims to:
– Identify patients who should undergo testing 
for NPC
– Raise awareness of the key signs and symptoms of 
NPC
– Exclude patients unlikely to have NPC
– In patients >4 years, prominent leading 
manifestation–associations were ataxia with 
dystonia, dysarthria/dysphagia, and cognitive 
decline. Psychosis was associated with 
dysarthria/dysphagia but also with cognitive decline 
and treatment-resistant psychiatric symptoms.
NPC Suspicion Index is a Simple-to-Use and Interactive Screening Tool
Available at: http://www.npc-si.com/symptoms/. Accessed November 2, 2017. 
Making a Diagnosis in Pediatric Patients
.
• Absence of a symptom checklist for identifying metabolic disease often means a lengthy wait before 
patients receive a diagnosis
Patients May See Numerous Specialists Prior to Receiving a 
Diagnosis of NPC
Niemann-Pick type C disease: Journey to Diagnosis. http://rqmo.org/wp-content/uploads/2015/01/Niemann-Pick-Enqu%C3%AAte-anglais.pdf. Accessed November 2, 2017.
Birth 19+ years
1 2 3 4 5 6
1st contact for patients 
(whose symptoms have 
been missed at birth) is 
Family Physician   or  
Pediatrician oftenly  
who has little or no 
experience of NPC
For patients with classic 
symptoms, recognition at 
birth leads to referral to a 
Gastroenterologist who 
may rapidly diagnose NPC
Where these symptoms are 
missed, patients remain in 
General  Medical Care, 
only achieving referral for 
treatment of individual 
symptoms as they become 
severe
Patients are cared for by 
several specialists at the 
same time, most of whom 
have little understanding of 
the implications of the 
symptoms outside their 
specialty
Patients in Psychiatric care 
already have a ‘diagnosis’ 
accounting for a variety of 
symptoms. As a result, the 
patient can be hidden in 
psychiatric care, seeing a 
series of specialists in mental 
illness who have little reason 
to suspect misdiagnosis
Symptoms such as 
hallucinations, aggressive 
behavior, or incoherent speech 
usually result in a relatively 
rapid referral to a Psychiatrist
and initiation of treatment for 
schizophrenia or bipolar 
disorder
Family Physician   or  
Pediatrician may 
refer the patient for 
counselling for mental 
illness or emotional 
disorders
Pediatricians Have a Fundamental Role Linking Symptoms Together to 










• History of prolonged neonatal cholestasis, hepatomegaly, and presence of splenomegaly 
in combination with clumsiness, frequent falls, or developmental delay could indicate NPC
• Symptoms might present at different times; some symptoms may appear to have been 
resolved
• Patient medical histories can often reveal unexplained cholestatic jaundice
• Although vertical supranuclear gaze palsy is a characteristic symptom of NPC and is 
present in nearly all cases, it is often missed, especially among younger patients
Presentation 
Differential Diagnosis
1. Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44. 2. Vanier MC, et al. Orphanet J Rare Dis. 2010;5(16):1-18. 3.Wijburg FA, et al. Neurology. 2012;78(20):1560-7.
In Some Cases, the Disease May Never be Detected or 













Idiopathic hepatitis. Biliary atresia .Galactosemia
Alpha 1 antitrypsin deficiency.Bile acid synthesis disorders
Cystic fibrosis .Tyrosinemia type I.
Peroxisomal disorders. Kernicterus 
(Bilirubin encephalopathy)
Early infantile (3m-2y) +






Sphingolipidosis (Gaucher .Niemann-Pick A and B)
Lipid storage disease (LAL-D). 
Glycogen storage disorders
Late infantile + 
Juvenile period (6-15y)
Dystonia 
Respiratory chain disorders .Pyruvate dehydrogenase 
deficiency .Vitamin E deficiency .Glucose transporter 1 
deficiency
Homocystinuria .Wilson disease, 
Urea cycle defects. Organic aciduria
Ataxia
Vitamin E deficiency. Mitochondrial disorders.
Autosomal recessive cerebellar ataxia (ARCA) Friedreich’s ataxia 
Vertical supranuclear 
gaze palsy ( usually 
downgaze first ) 
Progressive supranuclear palsy . Multiple system 
atrophy .Dementia with Lewy bodies.
Spinocerebellar ataxia .Tay-Sachs.
Thyroid disorders  (usually up gaze first) 
Wernicke encephalopathy.
Sporadic Creutzfeldt-Jakob.
Huntington’s. Wilson.Vitamin B12 
deficiency .Kernicterus.
Whipple disease (3 months to 81 years.)
Gelastic cataplexy Gelastic seizures Narcoleptic pentad
Juvenile period (6-15y) Psychosis
Hysteria, schizophrenia .Wilson disease.
Urea cycle defect. Homocystinuria




• Supportive therapies are variably effective for the alleviation of numerous clinical problems associated 
with the disease1
• Current therapeutic approaches focus on health-related quality of life, via multidisciplinary control of 
symptoms and their onset 2
There is Currently No Cure for NPC
Management strategies include non-specific, symptomatic treatments and NPC-
specific therapies1,3
Symptomatic therapies aim to improve a patient’s quality of life. 
However, they have no impact on disease progression or 
long-term outcomes1
Recent advances in the understanding of NPC pathophysiology 
have led to the development of an NPC–specific treatment, 
Miglustat, that can slow down the progression of the disease 1,4
Early diagnosis of NPC means that patients can access treatment and is crucial 
for timely intervention1
1. Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44. 2. Wraith JE, Imrie J. Understanding Niemann-Pick disease type C and its potential treatment. 2007. Blackwell Publishing, Oxford UK. 
3. Vanier MC, et al. Orphanet J Rare Dis. 2010;5(16):1-18. 4. Pineda M, et al. Mol Genet Metab. 2009;98:243-249.
• Symptomatic management includes gastrostomy to maintain caloric intake, antiepilepsy
drugs to prevent seizures, tricyclic antidepressants to control cataplexy, and 
anticholinergic drugs to treat dystonia and tremors
• Most treatments for NPC focus on symptomatic management to improve patient’s quality 
of life1
Current Approaches Target Symptoms and Focus on 
Health-related Quality of Life
1. Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44.
Current Approaches Target Symptoms and Focus on 




Seizures • Antiepileptic drugs
Cataplexy • Tricyclic antidepressants or CNS stimulants
Dystonia and tremor
• Anticholinergic drugs 
• Other drugs that can be effective: trihexyphenidyl, benzodiazepines, botulin toxin (selected 
cases), gamma-aminobutyric acid derivatives (advanced dystonia)
Dysphagia
• Softening or thickening of food
• Gastrostomy
Drooling
• Oral atropine, parotid/submandibular injections of botulinum toxin, hydroscine patches, or 
glycopyrronium bromide
Sleep disturbances • Melatonin or positive airway pressure
Cognitive impairment
• Support services
• Miglustat may stabilize cognitive decline
Psychiatric illness
Psychosis
• Atypical antipsychotics and regular neurological monitoring to minimize aggravation of 
preexisting dystonia
Catatonia • Electroconvulsive therapy
Bipolar disorder • Mood stabilizers (eg, sodium valproate)




• Antipropulsive agents (eg, loperamide) for diarrhea
• Bowel monitoring to prevent constipation in affected patients
Primary lung involvement • Aggressive bronchodilation and, in some cases, chest physical therapy
CNS, central nervous system.
Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44.
There Are Currently No Treatments For NPC That Directly Address The 
Pathophysiology Of Disease
• Miglustat is an iminosugar that reversibly inhibits the enzyme 
glucosylceramide synthase, the first committed step in 
glycosphingolipid synthesis2
• Although not approved in the United States for NPC,3
Miglustat is approved in Europe and other countries for the 
treatment of progressive neurological manifestations in adult 
and pediatric patients with NPC4
• Miglustat was approved in Europe based on the results from 
a small randomized controlled trial and its long-term 
extension studies, as well as a retrospective observational 
cohort study3
Inhibition of glucosylceramide synthase with Miglustat
Figure reproduced from Ficiciogly C. Ther Clin Risk Manag, 2008;4(2):425-31. 
• In the United States, Miglustat was approved only for the treatment of mild to moderate Type I Gaucher disease in adults who cannot 
use enzyme replacement1
• Outside the United States, Miglustat is approved for the treatment of NPC. Miglustat has demonstrated limited efficacy in stopping or 
delaying the progression of NPC in the majority of patients
1. Center for Drug Evaluation and Research Approval Letter. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-348_Zavesca_Approv.pdf. Accessed November 2, 2017. 2. Platt FM, et al. J Biol 
Chem. 1994;269(11):8362-5. 3. Zavesca (miglustat) (prescribing information). 2014; Actelion Pharmaceuticals US Inc; South San Francisco, CA. 4. Zavesca (miglustat) Summary of Product Characteristics. 
2016; Actelion Registration Ltd, London, UK. 
• Efficacy and safety of VTS-270 in patients (aged 4-21 years) with neurologic manifestations of NPC disease
• Onset of neurological symptoms prior to 15 years of age and confirmed diagnosis of NPC1 determined by either:
• 2 NPC1 mutations
• Positive filipin staining and ≥1 NPC1 mutation
• Vertical supranuclear gaze palsy plus either: one NPC1 mutation, OR positive filipin staining or oxysterol levels consistent with NPC disease and no 
NPC2 disease mutations
• Approximately two-thirds of patients will receive VTS-270 and the remaining study participants will receive sham control
• Aim to enroll 51 patients, estimated completion date: March 2018
VTS-270 Re-Establishes the Cell’s Ability to Transport and Regulate 
Cholesterol
Primary outcome measure 
(52 weeks)
• NPC Clinical severity score
Secondary outcome measures 
(52 weeks)
• Clinician and Caregiver Global Impression of Change
• Time to get up and go test
• 9-hole peg test
• Percentage of patients with clinical worsening




• Plasma protein biomarkers
Phase II/III Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease (NCT02534844)
Preliminary results from a Phase I/IIa study showed that administration of VTS-270 slowed and changed the course of disease progression
Ory DS, et al. Lancet. 2017;390:1758-1768.
• Currently, therapies are targeted at one or more 
pathologic features of NPC, and combinations of 
these small-molecule drugs have shown enhanced 
clinical benefit
• Individual treatments aim to:
– (1) reduce the accumulation of offending 
metabolites
– (2) bypass defective metabolic pathways 
– (3-5) enhance a cell’s resistance to disease 
– (6) increase/rescue function of existing NPC 
proteins .Molecular chaperone therapy only 
works with certain mutations : Gaucher's 
disease, Fabry disease, Pompe disease and 
Late-onset Tay-Sachs disease.
– (7-8) correct the primary metabolic defects
– (9) improve lysosomal function
Available Therapies Target One or More Pathological Features of NPC
HPBCD, 2-hydroxypropyl-beta-cyclodextrin. 
Davidson CC, et al. US Neurology. 2010;88-94.
Case Presentation
• 14-year-old female
• Hepatomegaly occurred at approximately age 6 years
• Developed dyspraxia, which manifested as slow running at the age of 8 years
• Bilateral dystonia was observed at age 10 years
• Scholastic achievement began to decline at age 12 years
Patient Presentation
Adapted from: Lorenzoni PJ, et al. Arq Neuropsiquiatr. 2014;72(3):214-218.
• Recent unexplained frequent falls and seizures reported by parents






How would you manage the patient at this point?
1. Referral for a neurological assessment
2. Referral for further testing (ie, MRI, laboratory analysis, genetic analysis)
3. Follow-up within 3 to 6 months
4. Consider a differential diagnosis
5. Other
MRI, magnetic resonance imaging.
Audience Question
How would you manage the patient at this point?
1. Referral for a neurological assessment
2. Referral for further testing (ie, MRI, laboratory analysis, genetic analysis)
3. Follow-up within 3-6 months
4. Consider a differential diagnosis
5. Other
ANSWER
MRI, magnetic resonance imaging.
• Diffuse cerebral and cerebellar atrophy was observed 
• Serum chitotriosidase levels were above normal limits 
• Bone marrow biopsy showed sea-blue histiocytes and foamy cells
• Skin fibroblast culture was atypical
Diagnostic Investigation
Results
Adapted from: Lorenzoni PJ, et al. Arq Neuropsiquiatr. 2014;72(3):214-218.
Diagnostic tests Result
Abnormal brain MRI +
High chitotriosidase level +
Sea-blue histiocytes at bone marrow +
Foamy cells at bone marrow +
Filipin staining +
Bone marrow biopsy showing sea blue histocytes with May-
Grumwalld-Giemsa staining or Niemann-Pick cells 
Audience Question
What would your differential diagnosis be?
1. Gaucher’s disease




What would your differential diagnosis be?
1. Gaucher’s disease




• Genetic testing revealed compound heterozygotic mutations in the NPC1 gene on alleles 1 and 2 
(A764V and A1035V, respectively)
Differential Diagnosis
Suspected NPC
Adapted from: Lorenzoni PJ, et al. Arq Neuropsiquiatr. 2014;72(3):214-218.
Early treatment in the disease course is associated with 
improved responses, 
highlighting the need for rapid diagnosis
• Early diagnosis is strongly influenced by symptoms presentation and speed of symptoms 
recognition
• There is a  low awareness about the metabolic storage diseases, such as NPC
• There is a need for improved education among healthcare professionals so that they can 
recognize the link between the symptoms that will  lead to the diagnosis of NPC
• There is a need for a greater focus on raising awareness of the classic symptoms in infants and 
for proactive testing of newborns with splenomegaly and / or hepatomegaly and severe jaundice 
before the symptoms subside
• For those patients whose first symptoms are learning and behavioral  difficulties, pediatricians
need to recognize and link symptoms together and think of a wider picture to allow 
multispecialty collaboration. 
• Unexplained  ‘’ Hepatosplenomegaly + Ataxia + Developmental delay + Eye movement 
abnormalities consider NPC ‘’
Summary
• Currently, there are no treatments for NPC that directly address the pathophysiology of 
disease; current management approaches of NPC have shown limited efficacy and focus 
on symptomatic treatment strategies
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• National Niemann-Pick Disease Foundation, Inc.
Email: nnpdf@nnpdf.org
Website: http://www.nnpdf.org
• CLIMB (Children Living with Inherited Metabolic Diseases)
Email: enquiries@climb.org.uk
Website: http://www.CLIMB.org.uk
• Genetic and Rare Diseases (GARD) Information Center
Website: http://rarediseases.info.nih.gov/GARD/
• GOLD, Global Organisation For Lysosomal Diseases
Email: enquiries@goldinfo.org
Website: http://www.goldinfo.org
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